{"id":"NCT04016779","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-20","primaryCompletion":"2020-10-10","completion":"2020-10-10","firstPosted":"2019-07-11","resultsPosted":"2022-07-12","lastUpdate":"2022-07-12"},"enrollment":374,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention-Deficit/Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["PBO"]},{"type":"DRUG","name":"SPN-812","otherNames":["Viloxazine extended-release capsules"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"SPN-812","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of SPN-812 (Viloxazine extended-release capsules; 200-600 mg) in adults 18-65 years of age with Attention-Deficit/Hyperactivity Disorder (ADHD).","primaryOutcome":{"measure":"Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-11.7,"sd":0.9},{"arm":"SPN-812","deltaMin":-15.5,"sd":0.91}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0040"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":["38824626","35896943"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Insomnia","Headache","Fatigue","Nausea","Decreased appetite"]}}